The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis. Clin Transl Allergy 2023 Jan; 13(1):e12219
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease. Clin Transl Allergy 2023 Jan; 13(1):e12221
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol 2022 Dec; 33(12):e13887
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients. Clin Exp Allergy 2022 Dec 22
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat 2023 Dec; 34(1):2161812
Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. J Am Acad Dermatol 2022 Dec 09
Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol 2022 Dec 07; 102:adv00830
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Eur J Pediatr 2023 Feb; 182(2):757-767
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry. Acta Derm Venereol 2022 Nov 24; 102:adv00820
Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 2022 Nov 24
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. Br J Clin Pharmacol 2023 Jan; 89(1):61-79
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry. JAMA Dermatol 2022 Dec 01; 158(12):1409-1413
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol 2022 Dec; 187(6):888-899
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. JAMA Dermatol 2022 Sep 01; 158(9):1048-1056
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study. Drugs Aging 2022 Sep; 39(9):715-727